Skip to content
value.today

BioClin Therapeutics, Inc.

🇺🇸 San Ramon, California, USABiotechnologyFounded 2010
Total raised
$86 M
5 rounds on record
Latest round
$10 M
Jul 2019
First round on record
Dec 2012
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of BioClin Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2019$10 MNo. 5$10 to $50 million

BioClin Therapeutics, Inc.: Raise no. 5, Jul 2019

Investors in this round

10 investors had bought by the notice of Jul 26, 2019: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $19 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Graeme M. Currie · Executive Officer · Chief Operating Officer
  • Julie M. Eastland · Executive Officer · Chief Financial Officer and Chief Business Officer
  • Scott D. Myers · Executive Officer, Director · Chairman, President, and Chief Executive Officer
  • Steve M. Abella · Executive Officer · Chief Medical Officer
  • Christian L. Richard · Director
  • David L. Kabakoff · Director
  • Fouad L. Azzam · Director
  • Joel L. Jean-Mairet · Director
  • Joseph L. Turner · Director
  • Marten L. Steen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offer and Sale of Convertible Promissory Notes and the shares issuable thereunder”

Signed by Max Barker, VP, Legal Affairs. Newest notice filed Jul 26, 2019. Read the notice at the SEC.

equity, debtSEC
Jan 2019$10 MNo. 4$10 to $50 million

BioClin Therapeutics, Inc.: Raise no. 4, Jan 2019

Investors in this round

10 investors had bought by the notice of Feb 12, 2019: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $20 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Graeme M. Currie · Executive Officer · Chief Operating Officer
  • Julie M. Eastland · Executive Officer · Chief Financial Officer and Chief Business Officer
  • Scott D. Myers · Executive Officer, Director · Chairman, President, and Chief Executive Officer
  • Steve M. Abella · Executive Officer · Chief Medical Officer
  • Christian L. Richard · Director
  • David L. Kabakoff · Director
  • Fouad L. Azzam · Director
  • Joel L. Jean-Mairet · Director
  • Joseph L. Turner · Director
  • Marten L. Steen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offer and Sale of Convertible Promissory Notes and the shares issuable thereunder”

Signed by Max Barker, VP, Legal Affairs. Newest notice filed Feb 12, 2019. Read the notice at the SEC.

equity, debtSEC
Mar 2017$50 MNo. 3$50 to $250 million

BioClin Therapeutics, Inc.: Raise no. 3, Mar 2017

Investors in this round

9 investors had bought by the notice of May 14, 2018: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Graeme L. Currie · Executive Officer · Chief Operating Officer
  • Stephen W. Lau · Executive Officer, Director · President, Chief Executive Officer, and Treasurer
  • Steve L. Abella · Executive Officer · Chief Medical Officer
  • Christian L. Richard · Director
  • David L. Kabakoff · Director
  • Fouad L. Azzam · Director
  • Joel L. Jean-Mairet · Director
  • Joseph L. Turner · Director
  • Marten L. Steen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offer and Sale of Series B Preferred Stock (and the shares issuable thereunder) and Special Voting Series B Preferred”

Signed by Stephen W. Lau, President & CEO. Newest notice filed May 14, 2018 (1 amendment). Read the notice at the SEC.

equitySEC
Apr 2014$6 MNo. 2$2 to $10 million

BioClin Therapeutics, Inc.: Raise no. 2, Apr 2014

Investors in this round

1 investor had bought by the notice of Apr 17, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric L. Yuen · Executive Officer
  • Kenneth L. Schwartz · Executive Officer
  • Stephen Lau · Executive Officer, Director
  • Jack L. Nielsen · Director
  • Joseph L. Turner · Director
  • Martin L. Steen · Director
  • Peter L. Moldt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stephen Lau, Chief Executive Officer. Newest notice filed Apr 17, 2014. Read the notice at the SEC.

optionsSEC
Dec 2012$10 MNo. 1$2 to $10 million

BioClin Therapeutics, Inc.: Raise no. 1, Dec 2012

Investors in this round

1 investor had bought by the notice of Jun 4, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stephen Lau · Executive Officer, Director
  • Joseph L. Turner · Director
  • Thomas L. Boone · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stephen Lau, Chief Executive Officer. Newest notice filed Jun 4, 2014. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • BioClin Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2019).

    SEC Form D · Jul 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2019

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of BioClin Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BioClin Therapeutics, Inc.
NameRoleNamed in
Graeme M. CurrieChief Operating OfficerJul 2019
Julie M. EastlandChief Financial Officer and Chief Business OfficerJul 2019
Scott D. MyersChairman, President, and Chief Executive OfficerJul 2019
Steve M. AbellaChief Medical OfficerJul 2019
Graeme L. CurrieChief Operating OfficerMay 2018
Stephen W. LauPresident, Chief Executive Officer, and TreasurerMay 2018
Steve L. AbellaChief Medical OfficerMay 2018
Brent D. FassettSecretaryMar 2017
Eric D. EmeryVice President ManufacturingMar 2017
Jocelyn D. HolashSenior Vice President, Translational SciencesMar 2017
Stephen LauExecutive officerJun 2014
Eric L. YuenExecutive officerApr 2014
Kenneth L. SchwartzExecutive officerApr 2014
Christian L. RichardDirectorJul 2019
David L. KabakoffDirectorJul 2019
Fouad L. AzzamDirectorJul 2019
Joel L. Jean-MairetDirectorJul 2019
Joseph L. TurnerDirectorJul 2019
Marten L. SteenDirectorJul 2019
Scott D. MyersChairman, President, and Chief Executive OfficerJul 2019
Stephen W. LauPresident, Chief Executive Officer, and TreasurerMay 2018
Cory L. FreedlandDirectorMar 2017
Stephen LauDirectorJun 2014
Thomas L. BooneDirectorJun 2014
Jack L. NielsenDirectorApr 2014
Martin L. SteenDirectorApr 2014
Peter L. MoldtDirectorApr 2014